Business
Manulife Announces Exclusive Partnership with Guardant Health to Bring the Shield Multi-Cancer Detection Test to Customers Across Asia
Manulife today announced an exclusive partnership with Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, becoming the first insurer in Asia to offer Guardant Health's Shield Multi-Cancer Detection (MCD) test to customers in Hong Kong, the Philippines, and Singapore. Under the partnership, Manulife's customers will have exclusive access to the Shield MCD test in these three launch markets in 2026, marking the first introduction of this innovative test in Asia to Manulife c
About this update from Manulife Financial Corporation
[{"type":"text","content":"First insurer in Asia to bring the innovative blood-based multi‑cancer screening solution to Hong Kong, Singapore, and the Philippines","length":134,"tagName":"p","attribs":{}},{"type":"text","content":"TSX/NYSE/PSE: MFC SEHK: 945","length":27,"tagName":"p","attribs":{}},{"type":"text","content":"HONG KONG, SINGAPORE, and MANILA, Philippines, March 16, 2026 /PRNewswire/ -- Manulife today announced an exclusive partnership with Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, becoming the first insurer in Asia to offer Guardant Health's Shield Multi-Cancer Detection (MCD) test to customers in Hong Kong, the Philippines, and Singapore. Under the partnership, Manulife's customers will have exclusive access to the Shield MCD test in these three launch markets in 2026, marking the first introduction of this innovative test in Asia to Manulife customers. This collaboration underscores both companies' shared commitment to expanding access to innovative and proven health solutions that address real, unmet health needs.","length":765,"tagName":"p"},{"type":"text","content":""By being the first insurer in Asia to offer the Shield MCD test, we're empowering our customers with a credible and valued service that encourages proactive health management", said Steve Finch, President and CEO of Manulife Asia. "This exclusive partnership demonstrates our commitment to offering innovative and differentiated solutions to improve the health outcomes of our customers."","length":413,"tagName":"p"},{"type":"text","content":"Cancer remains one of the leading causes of death in Asia1. With just a blood draw, the Shield MCD test screens for 10 of the most common cancers, many of which have high mortality rates in Asia. The test received Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) in June 2025.","length":306,"tagName":"p"},{"type":"text","content":"This collaboration builds on the two companies' existing relationship in Singapore to offer eligible customers access to the Guardant360 liquid biopsy test for advanced solid tumors and represents a shared vision of bringing new and advanced health solutions and expanding access to preventive care to more markets across Asia.","length":331,"tagName":"p"},{"type":"table","headerItems":[],"items":[{"val":[{"colspan...